Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 153-156
10.1182/blood-2022-167412